Showing posts with label Anti-Depressants. Show all posts
Showing posts with label Anti-Depressants. Show all posts

January 30, 2015

Friday, January 30, 2015
New research in Canada reveals that inflammation deep in the brain may be linked to depression.  Specifically, the Centre for Addiction and Mental Health (CAMH) studied the brain scans of patients with depression and those without.  Results showed 30% more inflammation in the brains of patients with clinical depression.  In addition, symptoms worsened with the degree of inflammation.  Keeping in mind that researchers only studied the scans of 40 patients, concrete conclusions are a tad premature.

Nevertheless, this research does offer new ideas for investigation, which could uncover other possible causes for the illness as well as potential new treatments for depression.  In other words, perhaps reducing inflammation in the brain may alleviate or eliminate the symptoms.  This is exciting news for the individuals that do not respond to medication, which, according to this research, consists of 30 to 50 per cent of patients!
“Inflammation is part of the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants.
[…] The purpose of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and to initiate tissue repair.
[…] Too little inflammation could lead to progressive tissue destruction by the harmful stimulus (eg. bacteria) and compromise the survival of the organism. In contrast, chronic inflammation may lead to a host of diseases, such as hay fever, periodontitis, atherosclerosis, rheumatoid arthritis, and even cancer (e.g., gallbladder carcinoma).”
According to Dr. Jeffrey Meyer of CAMH, it is theorized that the body of patients that have suffered some type of infection or trauma may have healed, however the brain has not had the opportunity to recover.  This may explain why patients with certain types of inflammatory disease, such as lupus, are several times more likely to develop clinical depression.

Of course, it is still unclear whether the inflammation in the brain occurs before depression sets in or as a result of the illness.
_______________________________________________

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called major depression, major depressive disorder or clinical depression, it affects how you feel, think and behave and can lead to a variety of emotional and physical problems. You may have trouble doing normal day-to-day activities, and depression may make you feel as if life isn't worth living.

During these episodes, symptoms occur most of the day, nearly every day and may include:
  • Feelings of sadness, emptiness or unhappiness
  • Angry outbursts, irritability or frustration, even over small matters
  • Loss of interest or pleasure in normal activities, such as sex
  • Sleep disturbances, including insomnia or sleeping too much
  • Tiredness and lack of energy, so that even small tasks take extra effort
  • Changes in appetite — often reduced appetite and weight loss, but increased cravings for food and weight gain in some people
  • Anxiety, agitation or restlessness — for example, excessive worrying, pacing, hand-wringing or an inability to sit still
  • Slowed thinking, speaking or body movements
  • Feelings of worthlessness or guilt, fixating on past failures or blaming yourself for things that are not your responsibility
  • Trouble thinking, concentrating, making decisions and remembering things
  • Frequent thoughts of death, suicidal thoughts, suicide attempts or suicide
  • Unexplained physical problems, such as back pain or headaches
Facts: 
  • Depression is a common mental disorder. Globally, more than 350 million people of all ages suffer from depression.
  • Depression is the leading cause of disability worldwide, and is a major contributor to the global burden of disease.
  • More women are affected by depression than men.
  • At its worst, depression can lead to suicide.
  • There are effective treatments for depression.
Study finds link between depression, brain inflammation
Inflammation
Depression (major depressive disorder)
Depression

© www.mentalhealthblog.com

August 22, 2010

Sunday, August 22, 2010

Ketamine is a fast-acting liquid anesthetic used mainly by veterinarians; it's also used in human medicine, even in children, because it doesn't depress breathing.

It's also an illegal club drug, known as "special K" or "vitamin K."

The street version is usually sold in a powder form that can be snorted or mixed into drinks, or dissolved into a liquid and injected.

It acts like LSD, causing vivid hallucinations in users and a sensation of floating outside their bodies.
Researchers at Yale University have discovered that a single dose of ketamine helps the brain to form new synaptic connections between neurons and can begin to relieve depressive symptoms in a little as 40 minutes.

In contrast, Prozac and other types of antidepressants can take anywhere from two weeks to a full month before they start to demonstrate any real results, in which benefits can only be seen in about a third of patients. This new antidepressant is now being tested in Canada with promising results.

Dr. James Kennedy, director of the neuroscience research department at the Centre for Addiction and Mental Health in Toronto states that ketamine might alleviate what has been known as a “major clinical problem”. The 2 - 4 weeks that patients await relief is a critical time where devastating outcomes, such as suicide, can occur because they begin to feel more energetic but depressive symptoms remain. Not only is there hope for those with difficult to treat depression, ketamine could actually save lives.
Earlier studies involving patients with "treatment-resistant" depression have found that those given a single dose of ketamine experience rapid and significant improvement in symptoms.

In a small study published earlier this month on patients with bipolar depression, 71 per cent of participants responded to ketamine versus six per cent who responded to placebo.
In addition to being fast-acting, studies show that relief can last for 7 – 10 days, according to professor of psychiatry and neurobiology at Yale, Ronald Duman, who calls ketamine a “magic drug”.

Duman also believes that this so-called magic drug may be able to reverse the effects of stress on the brain by repairing damaged connections between neurons caused by chronic stress.

Although ketamine may not be the ideal long-term solution for treating depression, it could certainly lead to the development of similar compounds that may produce the same effect, but can be more easily administered with less potential for abuse.

"Imagine someone who is in the ER (emergency department) and is highly suicidal. It would be a way to decrease the suicidal risk" says Dr. Pierre Blier, director of mood disorders research at the Institute of Mental Health Research and Canada Research Chair in Psychopharmacology at the Royal Ottawa Mental Health Centre, who has started using ketamine on some of his patients.

Sources:
'Magic drug' gives hope to bipolar patients - Ketamine is mainly used as an anesthetic by vets but shows promise in treating depression

© www.mentalhealthblog.com

June 30, 2010

Wednesday, June 30, 2010
A new study published in the Journal of Clinical Psychiatry has revealed that Omega-3 supplements can be an effective method of treating major depression in patients who do not have anxiety disorders.

At first glance, the efficacy of Omega-3 was not clearly demonstrated; however with further analysis it was clear that Omega-3 improved depressive symptoms as efficiently as those treated with antidepressants.

The experiment studied 432 male and female subjects with major depression over a period of 8 weeks, from October 2005 to January 2009. Each day of the study, half of the participants were given three capsules of OM3 Emotional Balance, a fish oil supplement which contains 1050 mg of eicosapentaenoic acid (EPA) and 150 of docosahexaenoic acid (DHA). The remaining participants took three identical capsules containing sunflower oil, which was flavored with fish oil to maintain the anonymity of the placebos. Researchers ensured a double-blind effect where neither subject nor researcher could identify either group.
“In contrast with typical clinical studies designed to assess the effectiveness of antidepressants, this study included a high proportion of patients with complex and difficult-to-treat conditions, including patients resistant to conventional antidepressant treatments and patients also suffering from an anxiety disorder. The aim was to assess the value of Omega-3 supplementation in a group of individuals more like those treated in outpatient clinics.”
Statistics show that roughly 11% of men and 16% of women in Canada are likely to suffer from major depression at some point in their lives. Currently, depression is listed as the world’s fourth leading cause of death and it is anticipated that it could be the second by the year 2020.
“Epidemiological and neurobiological studies have suggested that a relative deficit in polyunsaturated fatty acids of the Omega-3 group may predispose individuals to psychological disorders such as depression.”
Supplements are likely to be more attractive alternatives to the many patients with depression that cease pharmacotherapy after only a few months because of their fear of stigmatization or side effects. These alternatives need to be more adequately studied so that new treatments may be developed. Ideally, additional research directly comparing Omega-3 with conventional antidepressants could speed up the process toward more effective treatments for depression.

Treating Depression With Omega-3: Encouraging Results from Largest Clinical Study

© www.mentalhealthblog.com

May 1, 2010

Saturday, May 01, 2010
Contrary to popular belief, risks associated with alcohol consumption do not only strike the young. “A new study by researchers at the David Geffen School of Medicine at UCLA has found that more than a third of drinkers 60 years old and older consume amounts of alcohol that are excessive or that are potentially harmful in combination with certain diseases they may have or medications they may be taking.”

Researchers studied data from 3,308 older patients from primary care clinics in and around Santa Barbara, California. However, the sample used is more likely to be white, married, well-educated with high income. In addition, findings are based on self-reports, which also weakens the validity of this study.

Despite a clear lack of generalizability and reliability, researchers have found that the risk associated with drinking in older adults who already have certain illnesses or take medications while consuming alcohol are just as numerous as those at risk from alcohol consumption alone.

The Comorbidity Alcohol Risk Evaluation Tool (CARET) was used to assess drinking habits among these older adults. Results determined whether they were considered to be at risk if they fell into any of the following categories:
  • more than 2 drinks consumed on most days of the week

  • one to two drinks consumed on most days in combination with other illnesses like gout, hepatitis or nausea

  • one to two drinks consumed on most days in combination with medications, such as antidepressants or sedatives
The specific findings include:
  • 34.7 percent (1,147) of older adults were at risk due to drinking alone or to drinking in combination with comorbidities or medications, and 19.5 percent fell into multiple risk categories.

  • Of those at risk, 56.1 percent fell into at least two risk categories, and 31 percent fell into all three.

  • Participants who had not graduated from high school had 2.5 times the odds of at-risk drinking as those who had completed graduate school.

  • Respondents with annual household incomes between $80,000 and $100,000 had 1.5 times the odds of being at-risk as those with incomes under $30,000.

  • Respondents who were 80 or older had half the odds of at-risk drinking as those between the ages of 60 and 64.

  • Asians had less than half the odds of at-risk drinking as Caucasians.
Results must be taken with a grain of salt when applying them to the general population as a 62-year-old married white male with a high annual household income cannot compare to an 85-year-old widowed Asian female with a low an annual income. The study also makes no mention of drinking habits prior to older age.

Regardless of the various inconsistencies, results do suggest that Physicians may need to pay more attention to the drinking habits of certain older adults and any possible interactions that may exist between alcohol consumption and other illnesses or medications since this study has shown that as many as one in three older adults in this study’s sample that continue to drink into older adulthood are more at risk.

High Rates of at-Risk Drinking Among Elderly Adults, Study Finds

© www.mentalhealthblog.com

April 24, 2010

Saturday, April 24, 2010
The Buck Institute for Age Research has been studying the possibility that antidepressants and mood stabilizers, like lithium for example, could have positive effects on stroke victims. The growth of new neurons has been known to diminish the effects of a stroke as well as dramatically improve impaired functions after a stroke, while those types of medications have been found to encourage neurogenesis in rodents.
"What this study shows more convincingly than in the past is that the production of new neurons after stroke is beneficial in rodents," said Buck faculty member and senior author David Greenberg, MD, PhD. "Assuming that neurogenesis is also beneficial in humans, drugs approved by the FDA for other purposes and already shown to promote new neuron growth in rodents might be worth studying as a potential treatment for stroke in humans. For example, antidepressants are often used to treat post-stroke depression, but their potential for improving outcome from stroke itself is less certain."
Researchers compared the size of a stroke and the recovery from stroke in genetically altered mice that either had the ability to grow new neurons or not. It was discovered that mice without the ability to grow new neurons suffered strokes 30% larger; whereas the mice with the ability to grow new neurons showed dramatic improvement of motor functions following a stroke.

Although this new research sounds very exciting, Greenberg cautions that people should not attempt to treat themselves until clear evidence is made official as testing has not been rigorous enough to determine if negative effects exist or whether these positive effects can be seen in humans. Testing these medications that stimulate the growth of neurons could lead to other exciting discoveries for many other age-related disorders, such as Alzheimer’s, Parkinson’s and Huntington’s disease.
“Stroke is the third leading cause of death in the U.S. and is the leading cause of serious long-term disability in this country. Treatments for stroke are limited. Clot busting drugs, which have to be given within hours of the stroke, have been of great benefit to a small number of patients, but stroke is not usually diagnosed in time for them to be used.”
What is a stroke?

A stroke (sometimes called a cerebrovascular accident (CVA)) is the rapidly developing loss of brain function(s) due to disturbance in the blood supply to the brain, caused by a blocked or burst blood vessel. This can be due to ischemia (lack of glucose and oxygen supply) caused by thrombosis or embolism or due to a hemorrhage. As a result, the affected area of the brain is unable to function, leading to inability to move one or more limbs on one side of the body, inability to understand or formulate speech, or inability to see one side of the visual field.

What factors lead to a higher risk of stroke?
  • advanced age
  • hypertension
  • a previous stroke or transient ischemic attack (TIA)
  • diabetes
  • high cholesterol
  • cigarette smoking
  • atrial fibrillation
What are the symptoms of stroke?

Symptoms of a stroke that affects the central nervous system include:
  • hemiplegia and muscle weakness of the face
  • numbness
  • reduction in sensory or vibratory sensation
Generally, the symptoms affect one side of the body and the side affected is typically opposite to the affected brain area.

Symptoms of a stroke that affects the brain stem include:
  • altered smell, taste, hearing, or vision
  • drooping of eyelid and weakness of ocular muscles
  • decreased reflexes (gag, swallow, pupil reactivity to light)
  • decreased sensation and muscle weakness in the face
  • balance problems and nystagmus (involuntary eye movement)
  • altered breathing and heart rate
  • weakness in sternocleidomastoid muscle with an inability to turn the head to one side
  • weakness in tongue (inability to protrude and/or move from side to side)
Symptoms of a stroke that affects the cerebral cortex include:
  • aphasia (inability to speak or understand language from involvement of Broca's or Wernicke's area)
  • apraxia (altered voluntary movements)
  • visual field defect
  • memory deficits (with damage to the temporal lobe)
  • hemineglect (a deficit in attention to and awareness of one side of space is observed when there is damage to the parietal lobe)
  • disorganized thinking, confusion, hypersexual gestures (with damage to the frontal lobe)
  • anosognosia (persistent denial of the existence of a, usually stroke-related, deficit)
Symptoms of a stroke that affects the cerebellum include:
  • trouble walking
  • altered movement coordination
  • vertigo and or disequilibrium
What are the long-term effects?

Disability affects 75% of stroke survivors enough to decrease their employability. Stroke can affect patients physically, mentally, emotionally, or a combination of the three. The results of stroke vary widely depending on size and location of the lesion. Dysfunctions correspond to areas in the brain that have been damaged.

Some of the physical disabilities that can result from stroke include:
  • paralysis
  • numbness
  • pressure sores
  • pneumonia
  • incontinence
  • apraxia (inability to perform learned movements)
  • difficulties carrying out daily activities
  • appetite loss
  • speech loss
  • vision loss
  • pain
  • coma
  • death
Some of the mental disabilities that can result from stroke include:
  • anxiety
  • panic attacks
  • flat affect (failure to express emotions)
  • mania
  • apathy
  • psychosis
  • depression (characterized by lethargy, irritability, sleep disturbances, lowered self esteem, and withdrawal)
  • emotional lability (a rapid switch between emotional highs and lows and an inappropriate expression of emotions
  • speech problems
  • dementia
  • attention and memory problems
  • anosognosia (persistent denial of the existence of a, usually stroke-related, deficit)
  • hemispatial neglect (inability to attend to anything on the side of space opposite to the damaged hemisphere)
  • seizures
All resulting affects of stroke are dependent on the severity of brain damage.

Antidepressants as Treatment Immediately Following a Stroke?
Stroke

© www.mentalhealthblog.com

February 20, 2010

Saturday, February 20, 2010
A study in the British Medical Journal found that paroxetine, better known as paxil, decreases the benefits of the cancer treating drug tamoxifen. In addition, they found an increased risk of death in breast cancer patients the longer both drugs were taken concurrently.

Tamoxifen is a popular breast cancer treatment that can be taken for up to five years to prevent a recurrence. Conversely, paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is typically used to treat major depression, obsessive-compulsive, panic,social anxiety, and generalized anxiety.

Paroxetine has revealed promise for easing the hot flashes that can occur after cancer treatment. However, this anti-depressant has been known to have side effects such as nausea, somnolence, and sexual problems. This medication is also associated with significant weight gain and adult suicide.

Researchers studied the health records of 2,430 women taking tamoxifen between the years 1993 and 2005. They discovered that roughly 25% or 630 of these women were also taking paroxetine. Of the 1,074 women that died during this period, 374 of them died from breast cancer according to Ontario's cancer registry.
“Tamoxifen is an extremely important drug for breast cancer," said Dr. David Juurlink, a co-author of the study and a scientist at the Institute for Clinical Evaluative Sciences in Toronto. Paroxetine "takes that benefit away by interfering with the body's normal handling of tamoxifen. Specifically, researchers concluded that paroxetine blocks or inhibits an enzyme called cytochrome P450 2D6, which is needed to metabolize tamoxifen into its active form.
Although the evidence suggests that this anti-depressant must be stopped, researchers caution against abruptly ceasing treatment with paroxetine because of withdrawal effects and worsening of depressive symptoms.

Interestingly, the study did not find any increased risk of death among the smaller sample of women taking tamoxifen combined with some other SSRI, such as fluoxetine (Prozac), sertraline (Zoloft), citalopram (Celexa) and venlafaxine (Effexor). However, this smaller sample size may confound the study’s conclusiveness; however it does suggest that attractive alternatives exist.

Furthermore, there are always unanswered questions when it comes to research that focus on health records as several variables are unknown and uncontrolled. That being said, the slightest risk identified should be enough to stop using this medication, especially when there are equally effective substitutes.

Also, in recent news…
“In the first Paxil birth defect trial that resulted in a $2.5 million verdict against GlaxoSmithKline in October 2009, the infant, Lyam Kilker, was born with three heart defects; an atrial septal defect, a ventricular septal defect, and an interrupted aortic arch, after his mother took Paxil while pregnant.”
Antidepressant interferes with breast-cancer drug
Paroxetine
Paxil Birth Defect Trial - Battle of the Experts

© www.mentalhealthblog.com

January 8, 2010

Friday, January 08, 2010
“The Women's Health Initiative (WHI) of the National Institutes of Health followed more than 160,000 postmenopausal U.S. women for up to 15 years, examining risk factors for and potential preventive measures against cardiovascular disease, cancer and osteoporosis.”

The researchers collected data from 136,000 participants that were not taking antidepressant medications when they first began the study. It was noted during their first follow up between one and three years later that roughly 5,500 of those women had begun taking antidepressants. “The research team compared that group's subsequent history of cardiovascular disease with that of participants who had not started taking antidepressants.”

Results showed that the women taking antidepressants had a small, but statistically significant increased risk of stroke and/or death compared to participants declaring that they were not taking antidepressants.

Lead author, Jordan W. Smoller, MD, ScD, of the Massachusetts General Hospital (MGH) Department of Psychiatry, explains that although it is necessary to treat depression because it is a serious illness, it is equally important for older women to discuss their treatment options with their physician before committing to one because of the various risks involved.

The DSM IV defines depression as experiencing feelings of sadness, helplessness and hopelessness. It is a state of low mood and aversion to activity. Episodes of depressed mood are a core feature in various psychological disorders.

Some symptoms of depression can include:
  • Anxiety
  • Sleep disturbances
  • never seem to be enough
  • dullness
  • chronic sadness never seeming to end
  • obsessions
  • shakiness when feeling most down
  • mood swings
Medications used to treat depression:

Tricyclic antidepressants
  • Amitriptyline
  • Imipramine
  • Nortriptyline
  • Desipramine

  • Side effects: Fatigue, dry mouth, blurred vision, light-headedness
Selective serotonin-reuptake inhibitors (SSRI)
  • Fluoxetine
  • Fluvoxamine
  • Sertraline
  • Paroxetine

  • Side effects: Nausea, gastrointestinal upset, sleep disturbances, headache, agitation
Reversible inhibitors of monoamine oxidase:
  • Moclobemide

  • Side effects: Insomnia, headache, constipation
5-HT2 antagonists:
  • Nefazodone

  • Side effects: Fatigue, light-headedness, nausea, headache
Serotonin-norepinephrine reuptake inhibitors:
  • Venlafaxine

  • Side effects: Nausea, agitation, sweating
MAOIs (monoamine oxidase inhibitors):
  • Phenelzine (Nardil)
  • Tranylcypromine (Parnate)
  • Isocarboxazid (Marplan)
  • Selegiline (Emsam)

  • Side effects: Drowsiness, Constipation, Nausea, Diarrhea, Stomach upset, Fatigue, Dry mouth, Dizziness, Low blood pressure, Light-headedness, Decreased urination, Decreased sexual function, Sleep disturbances, Muscle twitching, Weight gain, Blurred vision, Headache, Increased appetite, Restlessness, Shakiness, Trembling, Weakness, Increased sweating
“Depression is a known risk factor for cardiovascular disease and premature death, and one of the reasons that tricyclic antidepressants are used less frequently is their potential for negative effects on heart function. Selective serotonin reuptake inhibitor (SSRI) antidepressants have fewer side effects in general and are known to have aspirin-like effects on bleeding, which could protect against clot-related cardiovascular disorders.”

Although no relationship was established between antidepressant use and heart disease, follow-up appointments nearly six years later indicated that participants using antidepressants had an increased risk of death and those treated with SSRIs had an increased risk of stroke.

Even though results seem frightening it seems to me that further investigation is needed as there are several problems with this study. The researchers have not distinguished whether the problem really lies within the link between antidepressants and cardiovascular disease or depression itself and cardiovascular disease. Prior studies will show that depression has risks that are just as high as those who use antidepressants in this study. If anything, the study may indicate that treatment with antidepressants could exacerbate those risks. After careful review of this study, it seems difficult to place blame on antidepressants, but more could be revealed with further investigation.

Additionally, the study does not specify whether these women were being treated for depression or for anxiety nor is there any indication that lifestyle factors such as stress, smoking or diet have been accounted for. Furthermore, the study is too group-specific; therefore it cannot suggest that results can be generalized to the other populations, such as men or premenopausal women unfortunately.

Despite the lack of concrete evidence, it seems logical that women with cardiovascular risks would benefit from exploring treatment options other than antidepressants, but in the end, for most, the benefits of antidepressants may far outweigh the costs.

Increased Risk of Death, Stroke in Postmenopausal Women Taking Antidepressants, Study Finds
Monoamine Oxidase Inhibitors
Medications for Treating Depression

© www.mentalhealthblog.com

May 27, 2008

Tuesday, May 27, 2008

New research suggests that religious leaders may have been sitting on a potential treatment for depression all along. Even hippies seem to have caught on to the healing powers of incense long before the academic world.

A team of researchers from John Hopkins University and the Hebrew University in Jerusalem studied the psychoactive effects of burning incense. Researcher, Raphael Mechoulam "found that incensole acetate, a Boswellia resin constituent, when tested in mice lowers anxiety and causes antidepressive-like behavior". Specifically, this constituent activates the TRPV3 protein in areas of the brain that are associated with emotions and nerves. These areas are the same as those already being activated by current medication in use for the treatment of depression and anxiety. Evidently, mice bred without this protein were not affected by the incense.

Although, the idea seems rather harmless in comparison to many of the medications on the market at this time, I have to wonder whether or not this might be a better alternative to medication. I am not convinced that this treatment holds much weight when considering the possible health risks associated with daily doses of incense inhalation in order to sufficiently reduce anxiety and depression.

© www.mentalhealthblog.com

April 11, 2008

Friday, April 11, 2008
As promised, here are some brief excerpts from my paper regarding the treatment of trichotillomania. This is simply a follow-up to the previous post: Assessment of Trichotillomania.

"Trichotillomania typically presents many challenges to effective treatment. The extant literature suggests that a minority of patients respond to a single intervention, for example, habit reversal or a specific pharmacological agent" (Christenson, Hollander & Stein, 1999, p. 93). Following careful investigation of data pertaining to treatment, findings point toward a high need for long-term controlled studies in order to determine the most appropriate methods for treating trichotillomania. The current research implies that there is no explicit procedure designed to be effective in all cases, rather because individuals have responded differently to various treatments and since studies have produced varied results, the ideal treatment could be some combination of techniques dependent on the individual. Because of this lack in concrete evidence to support the most successful method; this paper will explore the most effective treatment modalities currently in place. Accordingly, the existing appropriate methods are behavioural and pharmacotherapy or some combination of the two. There have been numerous techniques employed over the years; therefore a short review of these other methods will also be presented. [...]

Basically, in some form or another, HRT models consist of the following components: competing reaction training, awareness training, identifying response precursors, identifying habit prone situations, relaxation training, prevention training, habit interruption, positive attention (overcorrection), competing reaction, self-recording, display of improvement, social support and annoyance review (Christenson et al., 1999, p. 156). "Habit reversal training remains the most widely accepted treatment with the most convincing documentation of its efficacy" (Christenson et al., 1999, p. 161). [...]

Similar to behavioural treatment, pharmacotherapy has very little research to confidently support the most useful medications (Christenson et al., 1999, p. 171). Consequently, there has been a great deal of disagreement regarding the most effective medication to treat trichotillomania (Kelly et al., 2004, p. 5). That being said, there have been a multitude of medications prescribed over the years in an attempt to uncover the most effective drug. There is significant variability among medications due to the wide range of the disorder’s symptoms and the lack of long-term studies (Christenson et al., 1999, p. 96). [...]

"Treatment studies are plagued with conflicting results, a lack of large-scale controlled treatment trials, and limited long-term follow-up of patients" (Baer et al., 1998, p. 561). Because of this deficiency in terms of concrete support for the most effective method to treat trichotillomania; this paper has focused on exploring the most successful modalities presently in place. Therefore, behavioural and pharmacotherapy or some combination of the two have been considered as the most appropriate methods of treatment. Specifically, habit reversal treatment has proven to be the most successful form of behavioural treatment, while anti-depressants have been considered the most reliable medications currently being prescribed. In summary, thorough investigation has revealed a critical need for additional research of treatment modalities in order to ensure that the most effective methods are being applied in treating trichotillomania.

© www.mentalhealthblog.com

February 29, 2008

Friday, February 29, 2008
Finally, there’s more research suggesting the need to reduce the over-medicating of mental illness, specifically depression. The study conducted by Irving Kirsch of the University of Hull discovered that the benefits of anti-depressants, such as fluoxetine (Prozac), venlafaxine (Effexor), nefazodone (Serzone), and paroxetine (Seroxat / Paxil), are dependent upon the severity of the mental illness.

The study used a meta-analysis of data retrieved from trials supplied by the US Food and Drug Administration. “When the data from all of these trials had been put together, the improvement in depression amongst patients receiving the trial drug, as compared to those receiving placebo (dummy tablets), was not clinically significant in mildly depressed patients or even in most patients who suffer from very severe depression” – Article

It comes as no surprise that only a small group of participants actually benefited from their medications, and these patients tended to be those who suffered from severe depression to begin with. The severely depressed reaped fewer benefits from the placebo and more benefits from the actual medication than those less depressed. This not only suggests that anti-depressants serve their purpose for those who are really suffering, but it clearly demonstrates that not everyone needs to be medicated to function. Over-medicating is a serious problem within our society because it does seem easier to slap on a Band-Aid as opposed to working through months or even years of therapy. Unfortunately, the social and monetary cost of clinical therapy does not seem plausible for everyone in our society, however it hardly seems ethical or even productive to convert the depressed into addicts.

In my opinion, medication should always be the last resort when alternative measures are more proficient in treating mental illness.

© www.mentalhealthblog.com

Popular Posts

Dentalget.com is dental equipment supplier, we provide high quality dental instruments, dental handpiece at a discount price. Free shipping worldwide.

Categories

9/11 AADD Abortion Academic Success Acetylcholine ADD Adderall Addiction ADHD Adult Attention Deficit Disorder Adultery Advertising Aggression Aging Agreeableness AIDS Air Pressure Alcohol Alcohol Abuse Alcohol Dependence Alcoholism alpha-CaM kinase II Altitude Alzheimer's Amphetamine Amygdala Amyloid Amyloid Deposition Anesthesia Anger Anterior Cingulate Cortex Anterograde Amnesia Anti-Depressants Anti-Psychotic Anticholinergic Anticonvulsant Antiepileptic Antioxidants Anxiety Anxious-Avoidant Anxious-Preoccupied Apolipoprotein E Army Aromatherapy Asperger Syndrome Assessment Associative Learning Asthma Attachment Theory Attention Attention Deficit Disorder Attention Deficit Hyperactivity Disorder Autism Autism Spectrum Disorder Autonomic Nervous System Average Sleep Requirements B-type Natriuretic Peptide Babies Balance Behavioral Problems Behaviour Behavioural Impairment Behavioural Therapy Benadryl Bipolar Disorder Blood Clot Blood Pressure Blue Light Blue Light Goggles Body Mass Index Bone Marrow Brain Brain Development Brain Imaging Brain Injury Brain Stem Brain Surgery Breast Cancer Buddhism bullying Bupropion Business C-reactive Protein Calories CAMH Canada Canadian Charter of Rights and Freedoms Cancer Carbohydrates Cardiovascular Disease Care Facilities Caregiver cars Cdk5 Cell Phone Central Nervous System Centre for Addiction and Mental Health Cerebellum Cerebral Amyloid Angiopathy Cerebral Cortex Cerebrospinal Fluid Cerebrovascular Accident Cerebrovascular Insult Chat Rooms Chewing Childhood Disabilities Childhood Disintegrative Disorder Childhood Emotional Neglect Children Chitin Chitosan Cholesterol Choline Chromosome Chronic Pain Syndrome Chronic Stress Circadian Rhythm Cirrhosis Citalopram Classical Conditioning Climate Change Clot-Busting Drug Co-morbidity Cocaine Cognition Cognitive Development Cognitive Impairment Colloquially Brain Attack Coma Communication Device Communication Technology Concentration Concerta Concussion Conflict Confusion Conscientiousness Control Group Coordination Correlation Cortisol Counselling Couples CPAP Crack CRASH-2 CRASH-3 Creativity Criminal Code Cyberbullying Cyberpsychology Cyklokapron Daytrana Death Death Toll Decision-Making Declarative Memory Deep Brain Stimulation Delusion Dementia Dentures Depression Destrostat Deviant Behaviour Dexedrine Dextromethorphan Diabetes Diet Dietary Supplements Diphenhydramine Disability discrimination Dismissive-Avoidant Disorganized Attachment Disorganized Speech Disorientation Dizziness Docosahexaenoic Acid (DHA) Double-Blind Dream Drinking Drowsiness Drug Abuse Drug Dependence Drug Use Drugs DSM DSM-5 Dual Diagnosis Early Onset Alzheimer's Economic Crisis Ecstasy Effexor Ego Eicosapentaenoic Acid (EPA) Elderly Electrical Stimulation Electroconvulsive Therapy Electrodes Email Embitterment Embolic Emotion Emotional Neglect Emotional Problems Emotional Well-Being Employee Enrivonment Enzyme Epilepsy Estrogen Ethics Evolution Experimental Group Extracellular Signal-Regulated Kinase (ERK) Extroversion Facebook Facebook Fan Page Facebook Friends Family Family Therapy Fast Food Father Father Absenteeism Fatherhood FDA Fear Fearful-Avoidant FeelingBetterNow Fetus Fibrin Fish Oil fluoxetine fMRI Focalin Focus Food Fraud Friday Gamma Secretase Genetic Disorders Genetics Ginkgo Biloba Glucose Glutamate Receptor God Gout Guest Blogger Hair Pulling Haiti Hallucination Hallucinogenic Halo Effect Harm-Reduction Headache Healthy Eating Hearing Heart Attack Heart Disease Hematopoietic Stem Cells Hepatitis Hepatitis C Herbal Supplements Hereditary Angioedema Heredity Heroin High Blood Pressure Hippocampus Hockey Homelessness Hormone Housing Hox Genes Hoxb8 Cells Human Rights Hydromorphone Hyper-social Networker Hyperactivity Hypothalamus Illness Impulse Control Impulsivity Inattentiveness Infant Infidelity Inflammation Insecure Attachment Insomnia Instant Messaging Insulin Intellectual Development Intellectual Disability Internet Intracranial Bleeding Introversion Introvert Ischemic Stroke KASPAR Ketamine Ketogenic Kleptomania Laptop Latent Inhibition Learning Learning Disability Leukotrienes Limbic System Lithium Liver Locked-In Syndrome Long Term Memory Long-Term Potentiation Longevity Lupus Lysteda Maestro Rechargeable System Major Depression Mania MAOI Marriage MDMA Medication Meditation Melatonin Memory Memory Loss Memory Task Men Mental Health Mental Health Forum Mental Heath Mental Illness Metadate Metyrapone Mice Microglia Mild Cognitive Impairment (MCI) Mild Traumatic Brain Injury Military Mind-Body Mindless Eating Mitochondria MOHLTC Mood Disorder Morphine Mortality Rates MRI MS-275 Multiple Sclerosis Muscle Weakness music therapy Narcissism Natasha Richardson National Sleep Foundation Natural Disaster Nature/Nurture Nausea Necrosis Neglect Nerve Neuro-imaging Neurobiology Neurodegeneration Neurodegenrative Diseases Neurodevelopment Disorders Neurogenesis Neurological Disease Neuromarketing Neuron Neuropathy Neuroticism Neurotransmitter News Nintendo Wii Non-REM Sleep Nose Nurse Ratched Nutrition Obesity Obessive Compulsive Spectrum Disorder (OCD) Offspring Olfactory Gland OM3 Emotional Balance Omega 3 Ontario Ontario Review Board Ontario Works Opioid Oral Health Organic Ottawa Over-activity Over-Medication Ovulation Oxidative Cell Oxygen Oxytocin p35 Pacemaker Pain Pain Killer Pain Management Pancreatic Polypeptide Pancreatitis Paralysis Paranoia Paraskevidekatriaphobia Parenthood Parents Parkinson's Paroxetine Paxil PDD-NOS perception Perfume Peripheral Nervous System Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Pathway personality traits Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) PET Scan Pharmacology Phobias Physical Health Physiological Plasmin Plasminogen Plasticity Platelet-Activating Factor Politics Post-Concussion Assessment and Cognitive Test (ImPACT) Potassium Ion Channel Poverty Pregnancy Pressure Procedural Memory Promiscuity Prozac PsychBoard.com Psychiatric Ward Psychological Psychological Inventories Psychologist Psychology Psychology Forum Psychology of Eating Psychosis PTED PTSD Public Health Pyromania Quadriplegic Rehab Relationships Reliability Religion REM Research Retigabine Retrograde Amnesia Rett Syndrome Risperdal Ritalin road rage Robot Robotics Rodent Research Rosiglitazone Samsung Satiety Scales Schizophrenia School Screening Secure Attachment Sedatives Seizure Self-Affirmation Intervention Self-Confidence Self-Esteem Self-Integrity Self-Worth Semantic Memory Senior Seroquel Serotonin Serzone Sex Sex Therapy Sexual Orientation Sexual Satisfaction Shock Therapy Sideline Concussion Assessment Test (SCAT2) Sleep Sleep Apnea Sleep Disorders Sleep Quality Sleep Stages Smartphone Smoking Snacking Sniffing Technology Social Assistance Social Deficits Social Isolation Social Media Social Network Social Rejection Social Skills Social Worker Socialization Societal Change Soft Palate Soldier Somatic Nervous System Spatial Memory Special K Speech Spinal Cord Spinal Cord Injury Spinal Tap Sports Injury SSRI Statin Stem Cell Stimulant Strattera Stress Stress Hormone Stroke Substance Abuse Sugar Suicide Superstition Support Survey Suspicious Tablet Talk Therapy Tamoxifen Tanorexia Tax Payer Technology Television Telomere Temperature Testosterone Texting Therapy Thorazine Threshold Thrombosis Thrombotic Tinnitus Tissue Plasminogen Activator Topographical Disorientation Tranexamic Acid Trauma Treatment Tremors Trial Tribunal Trichotillomania Type-2 Diabetes Vagus Nerve Validity Ventromedial Prefrontal Cortex Video Games Virtual Reality Vision Visual Attention Vitamin B Vitamins Vitiligo Voice Vyvanse Walnuts Weight Loss Welfare Wellbutrin Wernicke–Korsakoff syndrome Wet Brain White Blood Cells Women Work World Health Organization Zileuton Zyban Zyprexa µ-opiate receptors (MOR)